Brief: Cytodyn Receives Positive Dsmc Recommendation After Interim Analysis For Leronlimab Phase 2B/3 Covid-19 Registrational Trial
20/10/2020 11:21
Oct 20 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN RECEIVES POSITIVE DSMC RECOMMENDATION AFTER
INTERIM
ANALYSIS FOR LERONLIMAB PHASE 2B/3 COVID-19 REGISTRATIONAL TRIAL
* CYTODYN INC - DSMC RECOMMENDS CYTODYN CONTINUE STUDY AS
PLANNED,
WITH PROTOCOL DEFINED SAMPLE SIZE AND POWER TO ACHIEVE PRIMARY
ENDPOINT
* CYTODYN INC - DSMC REQUESTS ANOTHER DATA REVIEW WHEN
ENROLLMENT
REACHES 293 PATIENTS (75%) TO ANALYZE ALL DATA, INCLUDING
SURVIVAL RATE AT 42 DAYS
Source text for Eikon: ID:nGNX15kSpH
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer